Orders and backlog rose 10% year-over-year, with revenue and adjusted EBITDA margin near guidance lows due to logistics and manufacturing inefficiencies. Protein Solutions outperformed with 11% revenue growth, while free cash flow and leverage improved significantly.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.